AI Article Synopsis
- The study assessed the effectiveness and safety of using topical bevacizumab in treating ocular surface squamous neoplasia (OSSN) in six patients over an 8-week period.
- Patients showed significant reduction in tumor size, with an average decrease of 43% in the first month and 68% in the second month; two patients had complete tumor disappearance, while four required surgical intervention.
- The research indicates that topical bevacizumab can be an effective neoadjuvant treatment for OSSN, potentially reducing the need for surgery in responsive cases, with no serious side effects observed.
Article Abstract
Purpose: To determine the efficacy and safety of topical bevacizumab treatment in patients with ocular surface squamous neoplasia (OSSN).
Methods: Six eyes of 6 patients with primary OSSN confirmed by impression cytology received topical 5 mg/mL bevacizumab 4 times daily for a period of 8 weeks. Patients were evaluated in 2-week intervals. Digital photography images were obtained at each visit and changes in the size of the lesions were analyzed by image analysis software.
Results: The mean age of the patients was 66 ± 13 (± SD) years. Four tumors were nasal in origin and 2 tumors were temporal. The mean reduction observed in the lesion area was 43% ± 24.2% (range, 20%-71%) in the first month and 68% ± 29.7% (range, 42%-100%) in the second month when compared with the baseline area. Four patients required tumor excision at the end of the treatment period. Surgical treatment was not necessary in 2 patients due to complete disappearance of the tumor, which was confirmed by impression cytology. The visual acuity was stable in all patients and no systemic or visual side effects were observed during the study period.
Conclusions: Topical bevacizumab is effective as a neoadjuvant therapy combined with surgical excision for the treatment of OSSN. Topical bevacizumab may be used before surgery to decrease the size of the excision. Excision may be unnecessary in responsive patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599122 | PMC |
| http://dx.doi.org/10.1089/jop.2014.0158 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Randomized Clinical Trial of Intraocular Pressure-Lowering Medications on Preventing Spikes in Intraocular Pressure Following Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
Ophthalmol Ther
December 2024
Department of Ophthalmology, Mettapracharak (Wat Rai Khing) Hospital, 52 Moo 2 Rai Khing Sam Pran, Nakhon Pathom, 73210, Thailand.
Introduction: Intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents are a primary management option for retinal diseases. Acute elevation of intraocular pressure (IOP) is a complication associated with these injections that should be considered. This study investigated and compared the prophylactic effects of fixed combination anti-glaucoma medication on IOP spikes following intravitreal anti-VEGF injections.
View Article and Find Full Text PDFMultimodal Imaging of a Unique Transitory Finding in Ocular Syphilis.
J Vitreoretin Dis
October 2024
Department of Ophthalmology, Weill Cornell Medicine, New York, NY, USA.
To describe a unique finding in ocular syphilis using multimodal imaging. A single case was analyzed. A 52-year-old man presented with chronic syphilitic posterior uveitis and was treated with intravenous and intramuscular penicillin for systemic manifestations, topical steroids, and unilateral bevacizumab for secondary macular neovascularization.
View Article and Find Full Text PDFDelayed and immediate cutaneous adverse events during pembrolizumab combination chemotherapy against cervical cancer: Case series.
J Dermatol
January 2025
Department of Dermatology, Keio University School of Medicine, Tokyo, Japan.
Article Synopsis
- Immune checkpoint inhibitors (ICIs), like pembrolizumab (PEM), are effective against tumors but can cause serious skin side effects (cutaneously adverse events or CAEs), especially when used in combination therapies.
- Severe CAEs may require stopping the immunotherapy, and the risk is higher when ICIs are used with other treatments compared to when they are used alone.
- A case study of 19 women with advanced cervical cancer highlighted the occurrence of severe CAEs, including erythema multiforme and anaphylaxis, stressing the need for tight monitoring of skin reactions during PEM combination therapy to ensure patient safety.
Ex vivo optical coherence tomography combined with near infrared targeted fluorescence: towards esophageal cancer detection.
Biomed Opt Express
October 2024
Department of Physics and Astronomy, LaserLab Amsterdam, Vrije Universiteit de Boelelaan 1081,, Amsterdam, The Netherlands.
Early detection of (pre)malignant esophageal lesions is critical to improve esophageal cancer morbidity and mortality rates. In patients with advanced esophageal adenocarcinoma (EAC) who undergo neoadjuvant chemoradiation therapy, the efficacy of therapy could be optimized and unnecessary surgery prevented by the reliable assessment of residual tumors after therapy. Optical coherence tomography (OCT) provides structural images at a (sub)-cellular level and has the potential to visualize morphological changes in tissue.
View Article and Find Full Text PDFIn silico evaluation of corneal patch eluting anti-VEGF agents concept.
Eur J Pharm Biopharm
November 2024
Centre for Advanced Materials and Technologies CEZAMAT, Warsaw University of Technology, Poland. Electronic address:
This study introduces a novel approach utilizing a temporary drug-eluting hydrogel corneal patch to prevent neovascularization, alongside a numerical predictive tool for assessing the release and transport kinetics of bevacizumab (BVZ) after the keratoplasty. A key focus was investigating the impact of tear film clearance on the release kinetics and drug transport from the designed corneal patch. The proposed tear drug clearance model incorporates the physiological mechanism of lacrimal flow (tear turnover), distinguishing itself from previous models.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!